The Collagen Founder
Who Walked Away:
"I Was Selling Women Half an Answer
and Calling It a Solution."

She has asked us not to use her name.

She has asked us not to name the brand she built, the investors she worked with, or the company that acquired her business three years ago. Her lawyers have seen this article. She is satisfied it contains nothing defamatory. She simply doesn't want to be found.

What she is willing to tell us is everything else.

She spent four years building one of the UK's fastest-growing marine collagen supplement brands. She was the founder, the face, and for a long period the primary evangelist — the woman you saw on the wellness podcasts, at the spa events, in the supplements aisle at Brown Thomas talking about bioavailability and peptide chains with the fluency of someone who had done her homework.

She had done her homework. That is precisely the problem.

She is talking now because she has spent the eighteen months since her exit reading — not the homework she did when she was building something, but the homework you do when you no longer have a financial interest in the answer. And what she has found, she says, is that the story she told for four years was true. It was just incomplete. And incomplete, in her assessment, is its own category of wrong.

Before we get to what she found, it helps to understand why collagen became the thing.

The UK collagen market is expected to grow from €20.4 million in 2023 to €28.8 million in 2028. Marine collagen is selling faster than almost any other supplement category in the country. Women are adding it to their morning coffee, their smoothies, their evening tea. They are spending €35 to €60 a month, consistently, for months and years at a time, because they have been told — accurately, and by people who believe it — that this will help their skin.

The reason they want to help their skin is not vanity in the trivial sense. It is the specific, well-founded anxiety of watching something structural change in your face after 40 and not knowing how to stop it.

She knows this anxiety because she had it herself. She built a brand from inside it.

"I started the company at 39. The age when you first notice that something is actually happening. Not ageing in the abstract way you worry about at 32. Actually happening. Your jawline, your cheekbones, your skin doesn't spring back the same way. I went looking for something to do about it. I found collagen. The studies looked compelling. I built a product I believed in."

She pauses.

"I also kept getting older while I was taking it every morning. My jawline kept softening. My skin kept changing. I told myself it would have been worse without the supplement. I believed that. I had to believe that."

She is careful to make this point clearly: the collagen supplement industry is not built on fraud. The studies exist. The mechanism is real. She understood it thoroughly and explained it accurately to every customer, investor and journalist who asked.

Here is the mechanism. When you consume collagen through powders or capsules, your body digests it into smaller peptides and amino acids. These peptides act like messengers, triggering your fibroblasts — collagen-producing cells — to work harder, resulting in firmer, more hydrated skin over time.

What she did not know — what nobody in her industry told her, what she did not think to look for — was what was happening on the other side of the equation while the supplements were doing their work.

She had been thinking about collagen like a tank that needed filling. Drink collagen, fill the tank. Simple. Logical. Profitable.

The tank had a hole in it. She had no idea.

The acquisition happened when the brand was four years old. She will not say who acquired them. She will say that the acquiring company's head of formulation — a biochemist with a serious CV and no interest in social niceties — asked a question during due diligence that she had never been asked before.

"Has your formulation team addressed the enzymatic destruction side of the collagen equation?"

She didn't understand the question. She said so.

The biochemist explained, with the patience of someone who had done this many times, that collagen loss in ageing skin is a two-sided problem. One side is the decline in production — fibroblasts slowing down, the body producing less collagen year on year. This is what supplements address. This is the side that gets all the marketing.

The other side is destruction.

Specifically: enzymes called matrix metalloproteinases — MMP-1 and MMP-3 — that actively break down existing collagen at the skin surface. These enzymes are present throughout life but accelerate significantly after 40. They are triggered by UV exposure, stress, and the simple biology of ageing. They work constantly. They do not respond to anything you swallow.

She sat in the boardroom and absorbed this.

She had spent four years selling women the production side of a two-sided problem. She had not known the destruction side existed.

She signed the acquisition documents. She sat in her car in the car park for forty minutes before she could drive home.

She spent the first three weeks after completion reading. Not the papers she'd been directed to by consultants who were being paid to support a product. The independent literature. The peer-reviewed studies with no industry funding.

What she found about MMP enzymes produced the specific quality of embarrassment that comes from realising you have been confidently wrong in public for a long time.

After the age of 25, collagen levels naturally decrease by about 1% per year. UV exposure, smoking, pollution and poor diet accelerate this loss, making skin thinner and less elastic over time. But the loss is not just a matter of slowing production. It is also a matter of accelerating destruction. MMP-1 and MMP-3 are the primary enzymes responsible for breaking down the collagen fibres that give skin its structure — the scaffolding that keeps the jaw defined, the cheeks lifted, the skin bouncing back. In your 20s these enzymes are kept in balance by natural inhibitors. After 40, the balance shifts. The inhibitors weaken. The enzymes accelerate.

Every time UV hits your skin — on the commute, at the school gate, through the office window — it activates these enzymes. Every unit of stress. Every disrupted night. All of it feeding the destruction that was happening the entire time she was telling her customers to fill the tank from the other end.

She tried to calculate, roughly, how much collagen she had signalled her body to produce in four years of daily supplementation. Then she tried to calculate how much of it MMP-1 and MMP-3 had been simultaneously dismantling at the skin surface. She stopped because the arithmetic was too uncomfortable.

Then she found bakuchiol.

She'd heard of it — vaguely, as a retinol alternative. What she had not known was that bakuchiol's primary clinical mechanism is the inhibition of MMP-1 and MMP-3. At 2% concentration — the dose used in the British Journal of Dermatology clinical trial — it specifically targets the enzymes that are destroying the collagen she had spent four years telling women to replenish from inside.

She read that three times.

The trial results: a 21% reduction in wrinkle surface area. A 22% improvement in skin texture and tone. In twelve weeks of consistent daily use. At 2% bakuchiol. No purging. No peeling. No recovery period. Just the enzyme destruction interrupted, and the skin allowed to rebuild what had been accumulating for years.

She went looking for who was using it at the right concentration.

The Concentration Gap — The Second Thing Nobody Told Her

She found that almost every product listing bakuchiol used it at 0.3%. Sometimes 0.5%. Rarely higher. The clinical trial used 2%.

She knew, from four years in the supplement industry, exactly why this gap exists. The clinical dose costs more to source. It requires specific formulation to remain stable and bioavailable. It makes the product more expensive to manufacture. So brands use a trace — enough to list the ingredient on the packaging, not enough to produce the mechanism the clinical research describes.

She had been in an industry that did precisely the same thing.

"When you're inside an industry, you develop a sophisticated eye for the gap between what the science says and what the marketing says — but only for your competitors. You never turn that eye on yourself. I was completely blind to the fact that the other side of the equation existed. We all have our version of the gap we don't look at."

She found Gentle & Rose through a biochemist she'd known from her brand-building years — someone with no connection to the acquisition and no reason to recommend anything. The biochemist mentioned it at dinner. Said the formulation was interesting. Said the bakuchiol concentration was one of very few she'd seen that matched the clinical literature.

She looked it up that evening.

Gentle & Rose is a small family business from the Kazanlak Valley in Bulgaria — the region that produces roughly 85% of the world's damascena rose oil. The same rose oil that Chanel sources at €6,000 to €8,000 per litre to dilute into fragrance at trace concentrations. The same oil that leaves this valley in tanker trucks every May and returns to European women in beautiful packaging at a hundred times the cost.

This family had decided to stop watching. They had taken the oil they kept back — the first pressing, the therapeutic grade — and formulated it alongside bakuchiol at 2% into a product built specifically around what skin after 40 actually needs. Not what is profitable to sell. What the independent peer-reviewed evidence says ageing skin requires.

Three ingredients. Clinical concentrations. No filler. No thirty-compound label designed to impress. She went to the product page expecting to pay significantly more than she'd been paying for the supplements.

She had spent, in four years of daily supplementation with her own brand's product, approximately €2,160. The product that addresses the side of the equation her supplements couldn't reach costs €39.

She ordered four bottles.

She is going to be specific about this. She spent four years communicating about results in careful, hedged, non-committal language. She has decided she is done with that.

Week One

The texture. She expected a serum. She got something that absorbed in seconds and left her skin feeling like skin — not like skin with something applied to it. She had used retinol through two consecutive winters and abandoned it by February both years because of the peeling and sensitivity. This had none of that. She used it every evening without exception.

Week Three

The grey lifted. The flat, dull quality her skin had developed since 43 — the one she'd been attributing to stress, or the aftermath of the acquisition, or simply what her skin looked like now — started to shift. Not dramatically. A quality of colour returning. Something alive that had not been there before.

Week Seven

She was doing her makeup when she stopped. The jawline. She is not going to claim it was dramatically restored. But the softness that had been settling there for three years was pulling back. Slightly. Measurably. She photographed it. She compared it to a photograph from seven weeks earlier. She sat on the edge of the bath for a moment with both photographs on her phone.

Month Four

A woman who has known her since university — a woman who says everything she thinks, because four decades of friendship gives you that permission — looked at her across a restaurant table and said: "What are you doing? Your skin looks like it did at 38."

She is 47. She has not had any procedures. She is using one product, every evening, that costs thirty-four pounds.

She cancelled her collagen subscription at month two. She has not reinstated it.

She wants to say something uncomfortable, and she wants to say it plainly.

The collagen supplement industry is not built on fraud. The studies exist. The mechanism is real. The hydration benefit is reasonably well-supported. She is not calling anyone a liar.

She is calling the industry structurally incurious about inconvenient information.

The MMP enzyme research has been in the peer-reviewed literature for decades. The clinical evidence on bakuchiol's MMP-inhibiting mechanism has been available since the mid-2010s. The reason nobody in the collagen supplement industry talks about the destruction side of the collagen equation is not ignorance — it is, she believes, a combination of competitive incentive and a very human tendency not to look carefully at the parts of the story that don't serve you.

Addressing the destruction side would require the supplement industry to say: the product you are buying from us is doing approximately half of the job. Here is the other half. We don't make it. But you need it.

No brand says this. No brand has a commercial incentive to say it.

She is aware that this article will be read as an endorsement of a specific product. She wants to address that directly.

She has no commercial relationship with Gentle & Rose. She reached the product through independent research and a recommendation from a biochemist with no connection to the brand. She is recommending it because the formulation aligns with what the independent clinical literature says skin after 40 actually needs.

She recommends Rose Youth Elixir for three specific reasons.

First: the bakuchiol concentration. 2%. The clinical dose. The one that actually inhibits MMP-1 and MMP-3 rather than appearing on a label at 0.3% as a marketing gesture. She has checked every product she could find. Very few use it at this concentration.

Second: the rose oil. Damascena, therapeutic grade, from the Kazanlak Valley. The same origin as the oil that goes into Chanel and Dior — at the concentration those houses never use. Barrier repair at a level that addresses oxidative damage in a way that applying hydration to the surface cannot.

Third: the price. She built a brand. She understands what things cost. €39 for this formulation is not a sign of a cheap product. It is a sign of a company that has decided to spend its margin on what's inside the bottle and nothing else.

She still takes collagen powder occasionally. She is not categorically anti-supplement. She is anti-incomplete. If you want to address skin ageing seriously after 40, you need both sides: the production and the destruction. One without the other is half a solution.

She spent four years selling half a solution. She would like, if possible, to stop watching other women do the same.

Over 80,000 women have now tried Rose Youth Elixir. Since she started talking about it — quietly, to people who ask her what she uses now — she has come across stories that map almost exactly onto her own.

She spent four years managing customer expectations about collagen results. She knows the language. She is not going to use it.

The existing damage — the lines already formed, the sagging already settled — takes time. The enzymes have been working for years. Interrupting them, and gradually reversing what they've accumulated, is not a two-week process. The British Journal of Dermatology trial ran for twelve weeks. The women who saw the 21% reduction in wrinkle surface area and the 22% improvement in skin texture were consistent daily users for three months.

What changes faster: the texture within the first week. The hydration and the grey lifting by week three. The structural changes — the jawline, the wrinkle depth, the firmness returning — come at ten to twelve weeks of daily use.

Two bottles minimum. One bottle shows you the mechanism. Two bottles shows you what your skin looks like when the destruction has been interrupted long enough for the result to be visible.

Gentle & Rose offer a 30-day return policy if it isn't right for you. They ship from Europe — 5 to 9 business days to Ireland, all duties and VAT included. They manufacture in small batches and they genuinely sell out. At the time of writing, fewer than 1,000 units remain from the current batch.

She cannot tell you for how long.